GSK Drugs - Search News

GSK to acquire US biotech group behind food allergy drug

GSK makes $2.2 billion swoop for RAPT Therapeutics' food allergy drug

Britain's GSK has agreed to buy RAPT Therapeutics for $2.2 billion, accessing the U.S. biotech's experimental drug to treat food allergies as it seeks new medicines ahead of patent losses for a top-selling HIV drug.

· 19h · on MSN

GSK announces $2.2 billion deal, targeting once-per-three-month food allergy drug

· 19h

GSK to buy US biotech behind food allergy drug for $2.2bn

GlobalData on MSN

GSK to file for approval of hep B drug on positive Phase III data

GSK will be filing for approval of bepirovirsen in hepatitis B to global regulatory authorities based on the Phase III data.

Zacks Investment Research on MSN

BMY vs GSK: Which biopharma giant has better prospects for now?

Bristol Myers Squibb BMY and GSK PLC GSK are among the largest global biopharma companies with broad and diverse portfolios.

Fierce Pharma

GSK licenses Alteogen enzyme in bid to develop subQ Jemperli

With star checkpoint inhibitors like Keytruda and Opdivo now sporting subcutaneous formulations, GSK has struck a deal aimed ...

MedCity News

GSK’s Respiratory Pipeline Adds an Early-Stage Drug Offering a Novel Approach to COPD

GSK’s respiratory drug lineup spans a newly approved product for chronic obstructive pulmonary disease as well as therapeutic candidates in various stages of clinical development for treating this ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results